American Century Companies Inc. grew its holdings in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 2.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,240 shares of the biopharmaceutical company’s stock after acquiring an additional 1,407 shares during the quarter. American Century Companies Inc. owned 0.09% of Portola Pharmaceuticals worth $2,990,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. IFP Advisors Inc boosted its position in shares of Portola Pharmaceuticals by 7.7% in the second quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 170 shares during the period. Ameritas Investment Partners Inc. bought a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $167,000. Credit Agricole S A bought a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $196,000. Amalgamated Bank bought a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $237,000. Finally, Aperio Group LLC bought a new stake in shares of Portola Pharmaceuticals in the second quarter valued at approximately $250,000. 85.27% of the stock is owned by institutional investors.
Portola Pharmaceuticals, Inc. (PTLA) opened at 56.96 on Wednesday. The company has a 50-day moving average price of $59.38 and a 200 day moving average price of $46.81. Portola Pharmaceuticals, Inc. has a 12 month low of $15.68 and a 12 month high of $67.10. The company’s market capitalization is $3.28 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.12). The company had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.28 million. Portola Pharmaceuticals had a negative net margin of 807.93% and a negative return on equity of 145.12%. The business’s revenue was down 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share. On average, equities research analysts forecast that Portola Pharmaceuticals, Inc. will post ($4.83) EPS for the current fiscal year.
In other news, EVP Tao Fu sold 5,812 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $65.00, for a total transaction of $377,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lis sold 269,299 shares of the company’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $55.43, for a total value of $14,927,243.57. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 589,656 shares of company stock valued at $32,818,131. Corporate insiders own 4.90% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $80.00 price objective on shares of Portola Pharmaceuticals in a research report on Wednesday, September 6th. BidaskClub raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price objective for the company in a research report on Wednesday, August 23rd. Zacks Investment Research cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Morgan Stanley increased their price objective on Portola Pharmaceuticals from $50.00 to $70.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $63.77.
Portola Pharmaceuticals Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.